China's Clinical Oncology Society Sets 12 GRADE-Rated Recommendations for Antiangiogenic TKIs in Sarcoma

Why a Chinese panel wrote this document now

The abstract sets out the gap it is answering. Chemotherapy still carries first-line treatment of advanced sarcoma, standard protocols for second line and beyond do not exist, and immunotherapy works in only a narrow set of subtypes. Against that, antiangiogenic TKIs have migrated from salvage use into first-line combination, maintenance and neoadjuvant settings, and the committee wrote the consensus to put boundaries around a drift that was already happening in practice. Two of the nine agents tabulated, anlotinib and apatinib, have no FDA-approved product in the United States at all, which shapes what a Chinese panel can put in a recommendation and what a European or American one could.

Ninety-five hours versus two and a half

The half-life table spans two orders of magnitude: anlotinib at 95 to 116 hours, cabozantinib at 55, fruquintinib at 35.2 to 48.5, sorafenib at 25 to 48, pazopanib at 31, lenvatinib at 28, regorafenib at 20 to 30, apatinib at 7.9 to 9.4, and axitinib at 2.5 to 6.1. A companion table converts those numbers into surgical instructions, giving a minimum interval between the last dose and a planned operation for each drug. Apatinib requires at least 30 days, cabozantinib at least 28, sunitinib at least three weeks, regorafenib at least two, pazopanib at least seven days and axitinib at least 24 hours. Antiangiogenic agents impair wound healing, and a sarcoma patient going to resection on one of the long-half-life drugs becomes a scheduling problem this table makes concrete.

Single-arm phase II counts as moderate evidence here

Level A in the committee's grading scheme requires multicenter randomized trials or meta-analyses. Level B, the moderate tier, explicitly admits high-quality single-arm phase II trials, and the committee annotates that category with the observation that such studies are very common in the sarcoma field, particularly for specific subtypes. Level C covers routine observational work and small single-center randomized trials, and level D covers case reports and expert opinion. Recommendation strength splits only two ways, strong or weak, with the weak grade reserved for situations where evidence certainty is insufficient and the decision has to be made against the individual patient.

Toxicity handled by grade, not by drug

Adverse event management is the fourth of the document's four main sections, and the approach is generic across the class. The dose strategy table keys off severity alone: grade 1 continues at the current dose with symptomatic care, grade 2 considers holding the drug and resuming at a 20% to 50% reduction, grade 3 holds and resumes reduced under close monitoring, and grade 4 stops immediately, with resumption only at a lower dose.

Where this sits against NCCN and ESMO

Nothing in the consensus is a regulatory action or an international guideline. The English abstract states the aim as guidance for Chinese clinicians, and the copyright sits with the Chinese Medical Association. The recommendation text itself, all 12 items and the reasoning behind each, appears only in the Chinese-language body of the paper, which the journal keeps behind a subscription. The tables, the section structure and the abstract were readable on the publisher's page. The wording of individual recommendations was not, so this article does not report which agent the panel favors for which subtype or line.

Why This Matters to the APO|APE Reader

The adverse event grading in this consensus runs against CTCAE version 6.0, a detail that matters for anyone trying to align a Chinese sarcoma dataset with a Western trial database still scoring on version 5.0. The washout spread is the second number to carry out of the paper: a service scheduling resection has to treat axitinib and cabozantinib as different classes of problem, 24 hours against 28 days, and no single institutional rule covers both. Sarcoma referral centers already field patients who started an antiangiogenic TKI elsewhere, and this document puts both numbers in one table with the panel's reasoning attached.